This key indicator collects data on the extent of infectious diseases — primarily HIV, hepatitis C and hepatitis B infection — among people who inject drugs (injecting drug users or IDUs). The data is collected from IDUs each calendar year using two main methods. These are: (a) surveys of IDUs that include serological testing and (b) the monitoring of routine diagnostic testing for HIV, hepatitis C and hepatitis B infection among IDUs. These two sources are the most useful as they can provide data on the proportion of those tested who are infected (i.e. prevalence).
Repeated collection of data over time allows examination of trends in prevalence, whilst collection of data from young or new users can provide an insight into current levels of transmission (i.e. incidence). In addition to the prevalence data, data on case reports of new diagnosis, such as data from national HIV case reporting and notification systems of hepatitis B and C, also provides useful information. The collection of infectious diseases data is undertaken by the EMCDDA in close collaboration with the EU Member States and the ECDC and WHO. Guidance on how this data should be collected has been produced by the EMCDDA. In addition, the data can be used to generate indirect estimates of the incidence, prevalence and trends in drug injecting (see the EMCDDA key indicator on problem drug use).
More information on the DRID key indicator can be found in the 'DRID toolbox' on this page.
The DRID toolbox provides access to a range of DRID-related material developed by the EMCDDA over the years. New resources will be added as they arrive. It is intended mainly for researchers and experts in the field of epidemiology.
The most recent work in DRID has resulted in a more flexible approach to DRID guidance, through a toolkit with modules and is principally aimed at professionals in the field. The first three modules were finalised in 2013 and cover: